Yu M C, Skipper P L, Taghizadeh K, Tannenbaum S R, Chan K K, Henderson B E, Ross R K
Comprehensive Cancer Center, University of Southern California, Los Angeles 90033-0800.
J Natl Cancer Inst. 1994 May 4;86(9):712-6. doi: 10.1093/jnci/86.9.712.
There is a large body of epidemiologic and experimental data that have identified a number of arylamines as human bladder carcinogens. Metabolic activation is required to biotransform these arylamines into their carcinogenic forms, and N-hydroxylation, which is catalyzed by the hepatic cytochrome P4501A2 isoenzyme, is generally viewed as the first critical step. On the other hand, the N-acetylation reaction, catalyzed by the hepatic N-acetyltransferase enzyme, represents a detoxification pathway for such compounds. The N-acetyltransferase enzyme is coded by a single gene displaying two phenotypes, slow and rapid acetylators. In the United States, cigarette smoking is a major cause of bladder cancer in men, and carcinogenic arylamines present in cigarette smoke are believed to be responsible for inducing bladder cancer in smokers.
Our purpose was to test the differences in three ethnic/racial groups for the prevalence of acetylator phenotypes and to ascertain whether slow acetylators actually have higher levels of activated arylamines in comparison with rapid acetylators.
One hundred thirty-three male residents of Los Angeles County who were either white, black, or Asian (Chinese or Japanese) and over the age of 35 years were assessed for their acetylator phenotype and levels of 3- and 4-aminobiphenyl (ABP) hemoglobin adducts. Subjects were either lifetime nonsmokers (n = 72) or current cigarette smokers of varying intensity (n = 61).
The proportion of slow acetylators was highest among whites (54%), intermediate among blacks (34%), and lowest among Asians (14%). Similarly, geometric mean levels of both 3- and 4-ABP-hemoglobin adducts were highest in whites (1.80 and 49.2 pg/g hemoglobin [Hb], respectively), intermediate in blacks (1.54 and 38.5 pg/g Hb), and lowest in Asians (0.73 and 36.0 pg/g Hb). As expected, cigarette smokers had significantly higher mean levels of both 3- and 4-ABP-hemoglobin adducts relative to nonsmokers, and the levels increased with the number of cigarettes smoked per day (P < .0005 for both adducts). Slow acetylators consistently exhibited higher mean levels of ABP-hemoglobin adducts relative to rapid acetylators, independent of race and level of smoking.
The present cross-sectional survey supports acetylation phenotype as an important determinant of bladder cancer risk and a possible major factor in the varying bladder cancer risk among whites, blacks, and Asians.
大量的流行病学和实验数据已确定多种芳基胺为人类膀胱致癌物。这些芳基胺需要通过代谢激活转化为致癌形式,而由肝细胞色素P4501A2同工酶催化的N - 羟基化通常被视为第一步关键反应。另一方面,由肝脏N - 乙酰转移酶催化的N - 乙酰化反应是此类化合物的一条解毒途径。N - 乙酰转移酶由一个单一基因编码,表现出两种表型,即慢乙酰化者和快乙酰化者。在美国,吸烟是男性膀胱癌的主要病因,香烟烟雾中存在的致癌芳基胺被认为是导致吸烟者患膀胱癌的原因。
我们的目的是检测三个种族/民族群体中乙酰化者表型的患病率差异,并确定慢乙酰化者与快乙酰化者相比,其活化芳基胺水平是否确实更高。
对洛杉矶县133名年龄在35岁以上的男性居民进行评估,他们分别为白人、黑人或亚洲人(中国人或日本人),评估其乙酰化者表型以及3 - 和4 - 氨基联苯(ABP)血红蛋白加合物水平。受试者要么是终生不吸烟者(n = 72),要么是不同吸烟强度的当前吸烟者(n = 61)。
慢乙酰化者的比例在白人中最高(54%),在黑人中居中(34%),在亚洲人中最低(14%)。同样,3 - 和4 - ABP - 血红蛋白加合物的几何平均水平在白人中最高(分别为1.80和49.2 pg/g血红蛋白[Hb]),在黑人中居中(1.54和38.5 pg/g Hb),在亚洲人中最低(0.73和36.0 pg/g Hb)。正如预期的那样,吸烟者的3 - 和4 - ABP - 血红蛋白加合物的平均水平相对于不吸烟者显著更高,并且随着每天吸烟数量的增加而升高(两种加合物的P均<0.0005)。与快乙酰化者相比,慢乙酰化者始终表现出更高的ABP - 血红蛋白加合物平均水平,与种族和吸烟水平无关。
本次横断面调查支持乙酰化表型是膀胱癌风险的重要决定因素,也是白人、黑人及亚洲人膀胱癌风险差异的一个可能主要因素。